Balance biotech with medtech investment, says VC firm
This article was originally published in Clinica
Although investing in biotechnology can yield rich rewards, it can be a long, expensive and ultimately highly risky activity. Medical technology investment, on the other hand, tends to offer less juicy returns, but it is a perfect complement in a properly diversified fund that is interested in spreading its risks and rewards over sectors and time. And according to Thom Rasche, newly appointed venture partner at international technology/healthcare venture capital fund Earlybird, there is a growing appetite among funds and investors for medtech.